Tempest Therapeutics Inc
Change company Symbol lookup
Select an option...
TPST Tempest Therapeutics Inc
PETV PetVivo Holdings Inc
KMI Kinder Morgan Inc
NXPL NextPlat Corp
D Dominion Energy Inc
CVS CVS Health Corp
CVI CVR Energy Inc
CTRE CareTrust REIT Inc
CSWC Capital Southwest Corp
CSCO Cisco Systems Inc
Go

Health Care : Biotechnology |
Company profile

Tempest Therapeutics, Inc. (Tempest) is a clinical-stage oncology company. The Company is focused on developing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a range of tumors. The Company’s two clinical programs include TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPARa). TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, and is in Phase I monotherapy and combination trials in solid tumors.

Closing Price
$1.85
Day's Change
-0.20 (-9.76%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.04
Day's Low
1.76
Volume
(Heavy Day)
Volume:
142,808

10-day average volume:
64,949
142,808

Marathon Shareholder Notice

9:36 pm ET March 13, 2023 (Newsfile) Print

New York, New York--(Newsfile Corp. - March 13, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Marathon Digital Holdings Inc. ("Marathon" or the "Company") (NASDAQ: MARA).

If you suffered losses exceeding $50,000 investing in Marathon stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may alsoclick here for additional information: www.faruqilaw.com/MARA.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/6455/158310_f48c90367419195d_001full.jpg



There is no cost or obligation to you.

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.

On February 28, 2023, Marathon issued press release announcing "that it has cancelled its webcast and conference call for the fourth quarter and fiscal year 2022, initially scheduled for today, February 28, 2023, at 4:30 p.m. Eastern time, and will postpone the publication of its corresponding financial results." The company also disclosed that on Feb. 22, Marathon received a comment letter from the Corporation Finance Staff of the U.S. Securities and Exchange Commission relating to issues including accounting matters.

The audit committee of Marathon's board concluded that audited financial statements in its Form 10-K for 2021 and unaudited statements for interim periods in several quarterly reports should no longer be relied upon.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/158310

comtex tracking

COMTEX_426532520/2523/2023-03-13T21:36:56

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.